Combination therapy for treatment of multi-drug resistant bacterial infections is becoming common. In vitro testing of drug combinations under realistic pharmacokinetic conditions is needed before a corresponding combination is eventually put into clinical use. The current standard for design of such in vitro simulations for drugs with different half-lives is heuristic and limited to two drugs. To address that void, we develop a rigorous design method suitable for an arbitrary number of drugs with different half-lives. The method developed offers substantial flexibility and produces novel designs even for two drugs. Explicit design equations are rigorously developed and are suitable for immediate use by experimenters. These equations were used in experimental verification using a combination of three antibiotics with distinctly different half-lives. In addition to antibiotics, the method is applicable to any anti-infective or anti-cancer drugs with distinct elimination pharmacokinetics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682276 | PMC |
http://dx.doi.org/10.1016/j.compchemeng.2021.107540 | DOI Listing |
Clin Microbiol Infect
December 2024
Medical Microbiology and Virology, Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.
Background: Despite established antiviral therapy for herpes simplex (HSV), varicella zoster (VZV) and cytomegalovirus (CMV) encephalitis, outcome remains poor.
Objectives: To assess pharmacokinetic (PK) and -dynamic (PD) data of antiviral drugs in the central nervous system (CNS) to optimize treatment of Herpesviridae encephalitis.
Sources: PUBMED search 1950 to September 2024, terms 1.
Int J Biol Macromol
December 2024
Department of Pharmaceutical Chemistry, M.R. College of Pharmaceutical Sciences and Research, Balisha-743234, India. Electronic address:
With cancer rates on the rise around the world, cancer treatment has dominated scientific discussions in recent years. The toxicity of cytotoxic drugs, their lack of tumor localization, and their uniform dispersion into tumor tissues are the obstacles to cancer therapy. Other cancer treatment drawbacks include short blood circulation half-lives and undesirable pharmacokinetic behavior.
View Article and Find Full Text PDFRecent Adv Drug Deliv Formul
December 2024
Parul Institute of Pharmacy, Parul University, Limda, Waghodia, Vadodara, Gujarat, 391760, India.
Nanostructured Lipid Carriers (NLCs) represent a promising advancement in the treatment of breast cancer, addressing the significant challenges posed by conventional chemotherapy, such as poor drug solubility, short half-lives, and high toxicity. This review delves into the potential of NLCs to overcome these limitations, highlighting their unique structure comprising a solid and lipid liquid core stabilized by surfactants. By examining diverse lipid blends used in the preparation of NLCs, the article emphasizes their suitability for targeted drug delivery.
View Article and Find Full Text PDFAntimicrob Agents Chemother
November 2024
Department of Molecular Microbiology and Immunology, St. Louis University School of Medicine, St. Louis, Missouri, USA.
We previously reported -hydroxypyridinedione (HPD) compounds with mid-nanomolar efficacy and selectivity indexes around 300 against hepatitis B virus (HBV) replication. However, they lack pharmacological evaluation. Here, we report anti-HBV efficacy, cytotoxicity, and pharmacological characterization of 29 novel HPDs within seven subgroups.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!